The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Extended follow-up report of a randomized phase II trial comparing gemcitabine and cisplatin with or without berzosertib in patients with advanced urothelial carcinoma.
 
Mamta Parikh
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb; Exelixis; Natera; OncoCyte; Sanofi/Aventis; Seagen
Research Funding - Karyopharm Therapeutics
 
Sumanta Kumar Pal
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
Paul Henry Frankel
Stock and Other Ownership Interests - Asensus Surgical; Geron
Consulting or Advisory Role - Johnson & Johnson/Janssen
 
Christopher Ruel
No Relationships to Disclose
 
Amir Mortazavi
Honoraria - Motive Medical Intelligence
Consulting or Advisory Role - Debiopharm Group; Pfizer; Seagen
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst)
 
Matthew I. Milowsky
Stock and Other Ownership Interests - Gilead Sciences; Merck; Pfizer
Consulting or Advisory Role - Loxo/Lilly
Research Funding - Accuray (Inst); Acrivon Therapeutics (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance Foundation Trials (Inst); ALX Oncology (Inst); Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); G1 Therapeutics (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Incyte (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); PCCTC (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - Elsevier; Medscape; Research to Practice
 
Ulka N. Vaishampayan
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Gilead Sciences; Merck Serono; Pfizer; Sanofi/Aventis
Speakers' Bureau - Bayer; Exelixis; Pfizer
Research Funding - Bristol-Myers Squibb; Merck KGaA
 
Yung Lyou
Consulting or Advisory Role - Pfizer/EMD Serono; Seattle Genetics/Astellas
Speakers' Bureau - Janssen Oncology
 
Peng Wang
No Relationships to Disclose
 
Rahul Atul Parikh
Stock and Other Ownership Interests - IBRX (I)
Patents, Royalties, Other Intellectual Property - Patents on DNA repair pathways in cancer. I do not receive any royalties for the same.
 
Benjamin A. Teply
Consulting or Advisory Role - Hospicom; Lilly; Pfizer/Myovant; Sanofi; SeaGen
Research Funding - Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); QED Therapeutics (Inst)
 
Robert Dreicer
Consulting or Advisory Role - Astellas Pharma; AVEO; Bayer; Gilead Sciences; Hinova Pharmaceuticals; Janssen Oncology; Merck; Pfizer; Seagen; Tavanta Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Seagen (Inst)
 
Hamid Emamekhoo
Consulting or Advisory Role - AVEO; Cardinal Health; Cardinal Health; Exelixis; Janssen Biotech; Seagen; Seagen
 
Dror Dror Michaelson
Employment - Cullinan Oncology (I)
Stock and Other Ownership Interests - Cullinan Oncology (I); Jounce Therapeutics (I)
Honoraria - Eisai; Exelixis; Janssen Oncology; Merck; Pfizer
Consulting or Advisory Role - Eisai; Exelixis; Janssen Oncology; Merck
Research Funding - Bristol Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst)
Expert Testimony - Bayer; EI Dupont
 
Christopher J. Hoimes
Honoraria - Seagen
Consulting or Advisory Role - 2bPrecise; Bristol-Myers Squibb; Eisai; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seagen
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Seagen
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); Bristol Myers Squibb Foundation (Inst); crispr therapeutics (Inst); Dynavax Technologies (Inst); Janssen Oncology (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); NanoCarrier (Inst); Nektar (Inst); NeoImmuneTech (Inst); Novartis (Inst); seagen (Inst)
(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst)
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Aptitude Health; Clinical Care Options; Curio Science; MJH Life Sciences; Peerview
Consulting or Advisory Role - Aravive; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Eisai; Exelixis; Janssen; Lilly; Merck; Pfizer; QED Therapeutics; Sanofi/Aventis; Seagen
Research Funding - Astellas Pharma; Janssen (Inst); Loxo/Lilly (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Janssen
 
Sandy Srinivas
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen Oncology; Merck; Novartis; Seagen
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Merck (Inst); Seattle Genetics/Astellas (Inst)
Other Relationship - Pfizer
 
William Y. Kim
Employment - Focal Medical, Inc. (I)
Leadership - Focal Medical, Inc. (I)
Stock and Other Ownership Interests - Abbvie; Abbvie; Amgen; Apellis Pharmaceuticals; Arvinas; Arvinas; BeiGene; Bristol-Myers Squibb; Kura Oncology; Moderna Therapeutics; Natera; Oramed; Revolution Medicines; Tango Therapeutics; Zentalis
Research Funding - Foundation Medicine; GeneCentric; Merck
Patents, Royalties, Other Intellectual Property - BASE47 bladder cancer subtype classifier; PurIST (Purity Independent Subtyping of Tumors) (I)
Other Relationship - Merck
 
Glenn Liu
Employment - AIQ Solutions
Leadership - AIQ Solutions
Stock and Other Ownership Interests - AIQ Solutions
Consulting or Advisory Role - Janssen medical Affairs
Research Funding - Johnson & Johnson (Inst); Madison Vaccines, Inc.; Novartis (Inst); Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - I have patent pending titled "System and method for evaluation of disease burden" which provides a novel method to identify and quantitate treatment response. (Inst)
 
Primo N Lara
Research Funding - AstraZeneca (Inst); Janssen Biotech (Inst); Taiho Pharmaceutical (Inst)